Drug Trial Radar · NCT03507790
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Oct 10, 2018
Primary completion
May 29, 2024
Study completion May 29, 2024
Sponsor
- Lead sponsor
- Cognition TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Apr 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
Conditions
- Mild to Moderate Alzheimer's Disease
Interventions
CT1812Drug
Active Study Drug
PlaceboDrug
Non-active study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 210 Days
- Number of Study Participants With at Least One Treatment Emergent Adverse Events (TEAs) and Serious Adverse Events (SAEs).Time frame: Up to 210 Days
Locations
32 sites in 5 countries. Site status is shown where the registry gives one.
21st Century Neurology/ Xenoscience Inc.
Phoenix, Arizona
Imaging Endpoints
Scottsdale, Arizona
Ki Health Partners, LLC dba New England Institute for Clinical Research
Stamford, Connecticut
JEM Research Institute
Atlantis, Florida
Charter Research
Lady Lake, Florida
ClinCloud, LLC
Maitland, Florida
Allied Biomedical Research Institute
Miami, Florida
Compass Research LLC- Bioclinica Research
The Villages, Florida
ClinCloud
Viera, Florida
Alzheimer's Memory Center
Charlotte, North Carolina
The Ohio State University - Wexner
Columbus, Ohio
Neuro Behavirol Clinical Research C
North Canton, Ohio
St Vincent's Hospital Sydney
Ivanhoe, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
Melbourne Health
Parkville, Victoria, Australia
Australian Alzheimer's Research Foundation
Nedlands, Western Australia, Australia
Neuro Health Centrum ltd
Brno, Czechia
NeuropsychiatrieHK S.R.O
Hradec Králové, Czechia
A-Shine S.R.O
Pilsen, Czechia
Clintrial S.R.O
Prague, Czechia
Neuropsychiatrie s.r.o.
Prague, Czechia
Forbeli S.R.O
Prague, Czechia
INEP
Prague, Czechia
Vestra Clinics
Rychnov nad Kněžnou, Czechia
Brain Research Den Bosch
's-Hertogenbosch, Netherlands
Brain Research Center Amsterdam
Amsterdam, Netherlands
Brain Research Center Zwolle
Zwolle, Netherlands
Fundación ACE
Barcelona, Spain
Hospital Clinico Universitario Virgen De La Arrixaca
El Palmar, Spain
Centro de Salud San Juan
Salamanca, Spain
Hospital Victoria EUGENIA. Unidad de Neurociencias.
Seville, Spain
Fundación Neuropolis - Hospital Viamed Montecanal
Zaragoza, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.